The present inventions relate to
- metallated porphyrin derivatives as ligands of G quadruplex and their use as anti-viral agents. Porphyrin derivatives candidates inhibits HIV replication with IC 50 around 100 nM in vitro.
More specifically, this application is related to the use of porphyrin derivatives as G-quadruplex ligands to inhibit viral infections, such as HIV, more particularly to inhibit HIV-1 replication cycle;
-methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one G4 forming sequence oligonucleotide;
- novel candidates for treating viral infections such as HIV, Epstein Barr virus, HPV (Papillomavirus), SARS coronavirus, Ebola virus, Marburg virus, Zika, Herpes (HHV) , Hepatitis B, Hepatitis C, Kaposi's sarcoma-associated herpesvirus (KSHV). In particular, the invention relates to novel compound derivatives that are shown to be G-quadruplex ligands and are thus useful for treating the above infections. Also the invention relates to the process of preparation of the novel compound derivatives.